Table 5.
Results of random effect network meta-analysis for exacerbation rate
| Comparators | Interventions
|
|||
|---|---|---|---|---|
| IND 150 μg
|
IND 300 μg
|
|||
| Rate ratio (95% CrI) |
P-value (better) %a |
Rate ratio (95% CrI) |
P-value (better) %a |
|
| PLBO | 0.729 (0.607, 0.866) | >99 | 0.817 (0.692, 0.959) | >99 |
| SAL 50 μg | 0.895 (0.737, 1.089) | 88 | 1.004 (0.834, 1.220) | 52 |
| FOR 12 μg | 0.845 (0.657, 1.072) | 93 | 0.945 (0.760, 1.159) | 73 |
| IND 150 μg | N/A | N/A | 1.128 (0.909, 1.378) | 13 |
| IND 300 μg | 0.897 (0.726, 1.100) | 87 | N/A | N/A |
| OLO 5 μg | 0.773 (0.590, 0.991) | 98 | 0.865 (0.674, 1.094) | 89 |
| OLO 10 μg | 0.737 (0.565, 0.939) | >99 | 0.826 (0.645, 1.035) | 96 |
Note:
a
P (better) denotes the probability that the intervention dose (column) is more effective than the comparator dose (row).
Abbreviations: 95% CrI, 95% credible interval; FOR, formoterol; IND, indacaterol; N/A, not applicable; OLO, olodaterol; PLBO, placebo; SAL, salmeterol.